There are currently 917 clinical trials in Washington, District Of Columbia looking for participants to engage in research studies. Trials are conducted at various facilities, including Children's National Medical Center, MedStar Georgetown University Hospital, MedStar Washington Hospital Center and Walter Reed Army Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH)
NCT02932410
Recruiting
This is a prospective, multicenter, open-label, randomized, controlled, parallel Phase 3 study with an open-label single-arm extension period to evaluate pharmacokinetics (PK), safety and efficacy of macitentan in children with pulmonary arterial hypertension (PAH).
Gender:
All
Ages:
Between 1 month and 17 years
Trial Updated:
06/18/2024
Locations: Children's National Medical Center, Washington, District of Columbia
Conditions: Pulmonary Arterial Hypertension
Register for Updates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
NCT05242484
Recruiting
The purpose of this study is to evaluate the efficacy and safety of JNJ-78934804 as compared to guselkumab and golimumab in participants with moderately to severely active ulcerative colitis who have had an inadequate initial response, loss of response, or intolerance to one or more approved advanced therapy.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
06/18/2024
Locations: MedStar Georgetown University Hospital, Washington, District of Columbia
Conditions: Colitis, Ulcerative
Register for Updates
Doxycycline for Emphysema in People Living With HIV (The DEPTH Trial)
NCT05382208
Recruiting
The purpose of this study is to determine if doxycycline will reduce progression of emphysema in people living with HIV. The secondary objectives are to examine the effects of doxycycline on change in quantity of emphysema, six minute walk distance, patient reported outcomes, ratio of forced expiratory volume in 1 second and forced vital capacity. Secondary objectives will also describe the safety and tolerability of doxycycline and determine if doxycycline is associated with development of ant... Read More
Gender:
All
Ages:
30 years and above
Trial Updated:
06/18/2024
Locations: DC VAMC, Washington, District of Columbia
Conditions: Emphysema, HIV
Register for Updates
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
NCT05757869
Recruiting
The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-central nervous system (CNS) systemic embolism.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: George Washington University School of Medicine, Washington, District of Columbia
Conditions: Atrial Fibrillation
Register for Updates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
NCT05242471
Recruiting
The purpose of this study is to evaluate the efficacy of JNJ-78934804 at Week 48 compared to guselkumab and golimumab.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
06/18/2024
Locations: MedStar Georgetown University Hospital, Washington, District of Columbia
Conditions: Crohn's Disease
Register for Updates
HEAL-LAA Clinical Trial
NCT05809596
Recruiting
The primary objective of this study is to collect real-world data on WATCHMAN FLX™ Pro Left Atrial Appendage Closure (LAAC) Device in patients with non-valvular atrial fibrillation.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Medstar Washington Hospital Center, Washington, District of Columbia
Conditions: Atrial Fibrillation, Bleeding, Stroke
Register for Updates
A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma
NCT06084884
Recruiting
A Phase I/II study to evaluate AZD5851 in patients with GPC3+ advanced/recurrent hepatocellular carcinoma.
Gender:
All
Ages:
Between 18 years and 130 years
Trial Updated:
06/18/2024
Locations: Research Site, Washington, District of Columbia
Conditions: Hepatocellular Carcinoma
Register for Updates
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
NCT05211895
Recruiting
This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) and domvanalimab (AB154) compared with durvalumab plus placebo in adults with locally advanced (Stage III), unresectable NSCLC whose disease has not progressed following definitive platinum-based cCRT.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Research Site, Washington, District of Columbia
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Ecopipam Tablets to Study Tourette's Disorder in Children, Adolescents and Adults
NCT05615220
Recruiting
This Phase 3 multicenter study evaluates the maintenance of efficacy, safety and tolerability of ecopipam tablets in children, adolescents and adults in the treatment of Tourette's Disorder (TD). The study includes an open-label period followed by double-blind, placebo-controlled, randomized withdrawal period.
Gender:
All
Ages:
6 years and above
Trial Updated:
06/18/2024
Locations: Childrens National Hospital, Washington, District of Columbia
Conditions: Tourette Disorder
Register for Updates
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
NCT05455320
Recruiting
The purpose of the study is to compare the efficacy of talquetamab subcutaneous(ly) (SC) in combination with daratumumab SC and pomalidomide (Tal-DP) and talquetamab SC in combination with daratumumab SC (Tal-D), respectively, with daratumumab SC in combination with pomalidomide and dexamethasone (DPd).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: MedStar Georgetown University Hospital, Washington, District of Columbia +1 locations
Conditions: Relapsed or Refractory Multiple Myeloma
Register for Updates
Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors
NCT05286801
Recruiting
This phase I/II trial studies how well tiragolumab and atezolizumab works when given to children and adults with SMARCB1 or SMARCA4 deficient tumors that have either come back (relapsed) or do not respond to therapy (refractory). SMARCB1 or SMARCA4 deficiency means that tumor cells are missing the SMARCB1 and SMARCA4 genes, seen with some aggressive cancers that are typically hard to treat. Immunotherapy with monoclonal antibodies, such as tiragolumab and atezolizumab, may help the body's immune... Read More
Gender:
All
Ages:
12 months and above
Trial Updated:
06/18/2024
Locations: Children's National Medical Center, Washington, District of Columbia
Conditions: Atypical Teratoid/Rhabdoid Tumor, Epithelioid Sarcoma, Kidney Medullary Carcinoma, Malignant Solid Neoplasm, Poorly Differentiated Chordoma, Recurrent Atypical Teratoid/Rhabdoid Tumor, Recurrent Chordoma, Recurrent Epithelioid Sarcoma, Recurrent Kidney Medullary Carcinoma, Recurrent Rhabdoid Tumor, Refractory Atypical Teratoid/Rhabdoid Tumor, Refractory Chordoma, Refractory Epithelioid Sarcoma, Refractory Kidney Medullary Carcinoma, Refractory Rhabdoid Tumor, Rhabdoid Tumor, Recurrent Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
Register for Updates
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT Study
NCT02997228
Recruiting
This phase III trial studies how well combination chemotherapy, bevacizumab, and/or atezolizumab work in treating patients with deficient deoxyribonucleic acid (DNA) mismatch repair colorectal cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Chemotherapy drugs, such as fluorouracil, oxaliplatin, and leucovorin calcium, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, o... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Kaiser Permanente-Capitol Hill Medical Center, Washington, District of Columbia
Conditions: Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7
Register for Updates